Allergan entered into a clinical trial agreement with Novartis to conduct a phase 2b study of Allergan’s cenicriviroc and Novartis’ lead FXR agonist in treating non-alcoholic steatohepatitis.
Allergan and Ironwood Pharmaceuticals, in partnership with the American Gastroenterological Association, launched a campaign focused on bowel health’s importance. Talk show host Wendy Williams served as the summit’s host.
Key Capital announced positive results for its liver cancer immunotherapy product hepcortespenlisimut-L. Key Capital proved the drug was safe and highly effective in treating 75 advanced liver cancer patients through a phase II study.
The FDA granted Bristol-Myers Squibb’s biologics license application for Opdivo priority review status. The FDA’s action date is Aug. 2.
Mauna Kea Technologies’ confocal laser endomicroscopy platform Cellvizio matches histologic diagnostic findings in relation to major gastrointestinal diseases. Researchers measured Cellvizio’s effectiveness against 399 prospective confocal laser endomicroscopy procedures between September 2013 and February 2015 at 12 participating centers.
More articles on gastroenterology:
GI leader to know: Dr. Megan Adkins Adams of Michigan Medicine Gastroenterology Clinic
Allergan collaborating with Novartis to treat non-alcoholic steatohepatitis: 4 notes
FDA encouraging development of new IBS therapies: 4 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
